Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 97

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Hodgkin's disease

Not recruiting

Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Follicle centre lymphoma follicular grade I, II - III

Not recruiting

Study Comparing Tisagenlecleucel with Standard Treatment for Adults with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Novartis Pharma AG

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-501A
  • Sponsor:Allogene Therapeutics Inc.

Febrile neutropenia

Not recruiting

Study on Shortening Antibiotic Treatment for Febrile Neutropenia in Hematology Patients Using Cefepime and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cefepime
  • Sponsor:UZ Leuven

Hodgkin's disease

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Diffuse large B-cell lymphoma+1

Not recruiting

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Chronic myeloid leukaemia

Not recruiting

Study of Asciminib Treatment for Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Bortezomib, and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Oslo University Hospital HF

Waldenstrom's macroglobulinaemia

Not recruiting

Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Acute myeloid leukaemia+1

Not recruiting

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Acute myeloid leukaemia+2

Not recruiting

Study Comparing Pevonedistat, Venetoclax, and Azacitidine with Venetoclax and Azacitidine in Adults with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Takeda Development Center Americas Inc.

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.